These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17487750)

  • 21. Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.
    Aydin D; Sendur MA; Kefeli U; Ustaalioglu BB; Aydin O; Yildirim E; Isik D; Ozcelik M; Surmeli H; Oyman A; Isik S; Sener N; Ercelep O; Odabas H; Aliustaoglu M; Gumus M
    Clin Colorectal Cancer; 2017 Mar; 16(1):78-83. PubMed ID: 27247089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
    Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):718-9. PubMed ID: 17274384
    [No Abstract]   [Full Text] [Related]  

  • 23. [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
    Li J; Xu JM; Li J; Zhang XD; Bai Y; Chu YP; Wang YH; Liu DQ; Jin ML; Shen L
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):225-7. PubMed ID: 18756942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
    Sogabe S; Yuki S; Takano H; Kobayashi Y; Nakatsumi H; Sasaki T; Kawamoto Y; Fukushima H; Iwanaga I; Uehata Y; Komatsu Y; Asaka M
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1375-7. PubMed ID: 21829085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
    Berlin J; Posey J; Tchekmedyian S; Hu E; Chan D; Malik I; Yang L; Amado RG; Hecht JR
    Clin Colorectal Cancer; 2007 Mar; 6(6):427-32. PubMed ID: 17531105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver metastasis from colonic adenocarcinoma presenting as nephrolithiasis: computed tomography findings.
    Abu-Ghanem S; Novik EF; Abu-Ghanem Y; Man S; Shelef I
    Isr Med Assoc J; 2011 Oct; 13(10):638-9. PubMed ID: 22097237
    [No Abstract]   [Full Text] [Related]  

  • 27. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
    Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
    Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
    J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
    Lorizzo K; Fazio N; Radice D; Boselli S; Ariu L; Zampino MG; Nolè F; Magni E; Ardito R; Minchella I; Rocca A; Di Meglio G; Squadroni M; de Braud F
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):301-6. PubMed ID: 19034450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination chemotherapy in advanced small bowel adenocarcinoma.
    Locher C; Malka D; Boige V; Lebray P; Elias D; Lasser P; Ducreux M
    Oncology; 2005; 69(4):290-4. PubMed ID: 16282708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
    Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishing a standard of care for small bowel adenocarcinomas: challenges and lessons learned.
    Halfdanarson TR; Grothey A
    Oncologist; 2012; 17(9):1133-4. PubMed ID: 22923454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
    Luo HY; Li YH; Zhang L; Jiang WQ; Shi YX; Wang F; He YJ; Xu RH
    Ai Zheng; 2007 Aug; 26(8):905-8. PubMed ID: 17697557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
    Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
    Seo MD; Lee KW; Lim JH; Yi HG; Kim DY; Oh DY; Kim JH; Im SA; Kim TY; Lee JS; Bang YJ
    Jpn J Clin Oncol; 2008 Sep; 38(9):589-95. PubMed ID: 18772169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy of irinotecan, 5-fluorouracil and leucovorin in patients with advanced rectal cancer. Report of two cases.
    Hasegawa H; Watanabe M; Baba H; Yoshinare K; Mukai M; Kubota T; Kitajima M
    Hepatogastroenterology; 2002; 49(46):891-3. PubMed ID: 12143234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.
    Chitapanarux I; Kamnerdsupaphon P; Lorvidhaya V; Siriwittayakorn P; Tharavichitkul E; Somwangprasert A; Sukthomya V
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):77-82. PubMed ID: 18195532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
    Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
    Seront E; Marot L; Coche E; Gala JL; Sempoux C; Humblet Y
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S11-4. PubMed ID: 20189054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.